{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:36Z","timestamp":1790887776854,"version":"4.1.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T00:00:00Z","timestamp":1397433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0094294","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T20:30:50Z","timestamp":1397507450000},"page":"e94294","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":96,"title":["Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS\/TEN in Thai Population"],"prefix":"10.1371","volume":"9","author":[{"given":"Surasak","family":"Saokaew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichittra","family":"Tassaneeyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratree","family":"Maenthaisong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331(19)","author":"JC Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Sevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126(1)","author":"H Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiform emajus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49(7)","author":"B Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review","volume":"39(6)","author":"R Gerull","year":"2011","journal-title":"Crit Care Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"T Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62(5)","author":"LW Yip","year":"2007","journal-title":"Allergy"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","article-title":"Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome","volume":"112(5)","author":"MA Di Pascuale","year":"2005","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"R Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"MLS Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref10","unstructured":"Rheumatism Association of Thailand (2012) Guideline for management of gout Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/thairheumatology.org\/attchfile\/Guideline%20for%20Management%20of%20Gout.pdf\" xlink:type=\"simple\">http:\/\/thairheumatology.org\/attchfile\/Guideline%20for%20Management%20of%20Gout.pdf<\/ext-link>.Accessed 17 August 2013."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","article-title":"Recommendations for the diagnosis and management of gout and hyperuriccemia","volume":"123(6","author":"M Hamburger","year":"2011","journal-title":"Postgrad Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/2040622312462056","article-title":"Latest evidence on gout management: what the clinician needs to know","volume":"3(6)","author":"CM Burns","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200666120-00002","article-title":"Pathophysiology, clinical presentation and treatment of gout","volume":"66","author":"GG Teng","year":"2006","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for management of gout. Part 1: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64(10)","author":"D Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"W Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"J Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"JT Scott","year":"1966","journal-title":"Ann rheum Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","article-title":"Gout and hyperuricemia","volume":"14","author":"RL Wortmann","year":"2002","journal-title":"Curr Op in Rheumatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","article-title":"Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department \u2013 Cagliari University (Italy)","volume":"26(11)","author":"L Atzori","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19(9)","author":"W Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref21","first-page":"S1","article-title":"Thai health technology assessment guideline","volume":"91(2)","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"ref22","unstructured":"Riewpaiboon A. (2010) Standard cost lists for health technology assessment. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hitap.net\/costingmenu\/\" xlink:type=\"simple\">http:\/\/www.hitap.net\/costingmenu\/<\/ext-link>. Accessed 27 July 2013."},{"key":"ref23","first-page":"28","article-title":"Report of drug-related severe cutaneous adverse reaction: SJS\/TEN","volume":"4(1)","author":"W Suwankesawong","year":"2011","journal-title":"Med Health Prod Bull1"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts","volume":"86","author":"F Perez-Ruiz","year":"2000","journal-title":"Nephron"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysisdisease spectrum","volume":"102(11)","author":"WJ Power","year":"1995","journal-title":"Ophthalmology"},{"key":"ref26","first-page":"467","article-title":"Prevalence and mortality rate of severe cutaneous adverse reactions in Siriraj hospital","volume":"54(5)","author":"S Limkobpaiboon","year":"2010","journal-title":"Chula Med J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1399-0039.2010.01448.x","article-title":"HLA class I and II alleles and haplotypes in ethnic Northeast Thais","volume":"75","author":"AV Romphruk","year":"2010","journal-title":"Tissue Antigens"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Research 39, D913\u2013D919 Available <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.allelefrequencies.net\/Accessed\" xlink:type=\"simple\">http:\/\/www.allelefrequencies.net\/Accessed<\/ext-link> 14July 2013.","DOI":"10.1093\/nar\/gkq1128"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(67)90514-4","article-title":"The clinical application of Bayes&apos; theorem","volume":"2(7515)","author":"GH Hall","year":"1967","journal-title":"Lancet 9"},{"key":"ref30","unstructured":"World Health Organization (2011) Global Health Observatory Data Repository. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/ghodata\/?vid=61640\" xlink:type=\"simple\">http:\/\/apps.who.int\/ghodata\/?vid=61640<\/ext-link>. Accessed 17 June 2012."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Beard SM, von Scheele BG, Nuki G, Pearson IV (2013) Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ: DOI 10.1007\/s10198-013-0486-z.","DOI":"10.1007\/s10198-013-0486-z"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease","volume":"110(7)","author":"RM Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1542-0124(12)70043-5","article-title":"Utility assessment to measure the impact of dry eye disease","volume":"4(3)","author":"P Buchholz","year":"2006","journal-title":"Ocul Surf"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MLR.0b013e318234a04a","article-title":"Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods","volume":"50(5)","author":"R Ara","year":"2012","journal-title":"Med Care"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","article-title":"Diagnostic tests 2: predictive values","volume":"309(6947)","author":"DG Altman","year":"1994","journal-title":"BMJ"},{"key":"ref36","first-page":"1","article-title":"A review of near patient testing in primary care","volume":"1(5)","author":"FD Hobbs","year":"1997","journal-title":"Health Technol Assess"},{"key":"ref37","unstructured":"Bank of Thailand (2013) Foreign Exchange Rates. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bot.or.th\/english\/statistics\/financialmarkets\/exchangerate\/_layouts\/application\/exchangerate\/exchangerate.aspx\" xlink:type=\"simple\">http:\/\/www.bot.or.th\/english\/statistics\/financialmarkets\/exchangerate\/_layouts\/application\/exchangerate\/exchangerate.aspx<\/ext-link>. Accessed 8 July 2013."},{"key":"ref38","unstructured":"Wises K, Chunhasewee S, Rattanapan P (2008) Cost of management for Stevens-Johnson Syndrome or toxic epidermal necrolysis. Phitsanulok: Naresuan University."},{"key":"ref39","unstructured":"Drugs and Medical Supplies Information Center (DMSIC), Ministry of Public Health. (2013) Reference drug price. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dmsic.moph.go.th\/price\/price1_1.php?method=drug\" xlink:type=\"simple\">http:\/\/dmsic.moph.go.th\/price\/price1_1.php?method=drug<\/ext-link>. Accessed 9July 2013."},{"key":"ref40","unstructured":"Bureau of trade and economic indices, Ministry of Commerce Thailand (2013) Report of consumer price index of Thailand. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.price.moc.go.th\/content1.aspx?cid=1\" xlink:type=\"simple\">www.price.moc.go.th\/content1.aspx?cid=1<\/ext-link>. Accessed 7July 2013."},{"key":"ref41","unstructured":"Ministry of Public Health (2009) Public Health Statistics. Bangkok."},{"key":"ref42","first-page":"S53","article-title":"Handling time in economic evaluation studies","volume":"91(Suppl2)","author":"U Permsuwan","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"ref43","unstructured":"Sub-committee of Thai Working Group on Health Technology Assessment (2013) Meeting report of 2<sup>nd<\/sup> annual meeting."},{"key":"ref44","unstructured":"Limwattananon S (2008) Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai (Suppl 2):S59\u2013S65."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17(5)","author":"AH Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"ref46","unstructured":"Teerawattananon Y, Chaikledkaew U (2008) Thai health technology assessment guideline development. J Med Assoc Thai (Suppl 2):S11\u2013S15."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0094294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:03:16Z","timestamp":1540296196000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0094294"}},"subtitle":[],"editor":[{"given":"David W.","family":"Dowdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,14]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0094294","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,14]]}}}